Research ArticleArticle
Open Access
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
Arthur Kavanaugh, Rene R. Westhovens, Kevin L. Winthrop, Susan J. Lee, YingMeei Tan, Di An, Lei Ye, John S. Sundy, Robin Besuyen, Luc Meuleners, Mykola Stanislavchuk, Alberto J. Spindler, Maria Greenwald, Rieke Alten and Mark C. Genovese
The Journal of Rheumatology February 2021, jrheum.201183; DOI: https://doi.org/10.3899/jrheum.201183
Arthur Kavanaugh
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Rene R. Westhovens
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Kevin L. Winthrop
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Susan J. Lee
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
YingMeei Tan
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Di An
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Lei Ye
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
John S. Sundy
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Robin Besuyen
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Luc Meuleners
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Mykola Stanislavchuk
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Alberto J. Spindler
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Maria Greenwald
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Rieke Alten
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
Mark C. Genovese
This study was funded by Gilead Sciences Inc. A. Kavanaugh, MD, University of California San Diego, La Jolla, California, USA; R.R. Westhovens, MD, PhD, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; K.L. Winthrop, MD, MPH, Oregon Health and Science University, Portland, Oregon, USA; S.J. Lee, MD, Y. Tan, PhD, D. An, PhD, L. Ye, PhD, J.S. Sundy, MD, PhD, Gilead Sciences Inc., Foster City, California, USA; R. Besuyen, MD, L. Meuleners, MS, Galapagos NV, Mechelen, Belgium; M. Stanislavchuk, MD, National Pirogov Memorial Medical University, Vinnytsya, Ukraine; A.J. Spindler, MD, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; M. Greenwald, MD, Desert Medical Advances, Palm Desert, California, USA; R. Alten, MD, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; M.C. Genovese, MD, Stanford University School of Medicine, Division of Immunology & Rheumatology, Stanford, and Gilead Sciences Inc., Foster City, California, USA. AK has received consulting fees from Gilead Sciences Inc. RW has received consulting fees from Celltrion, Galapagos, Gilead Sciences Inc., Bristol Myers Squibb, and Roche. KW has received consulting fees from Gilead Sciences Inc., Galapagos, AbbVie, Eli Lilly, and Pfizer. SL, YT, DA, LY, and JS are employees of Gilead Sciences Inc. RB and LM are employees of Galapagos NV. MG has received consulting fees from Celgene, Bristol Myers Squibb, Gilead Sciences Inc., Eli Lilly, Pfizer, AbbVie, Fuji, and Novartis. RA has received consulting fees from Gilead Sciences Inc. and Galapagos. MG has received consulting fees from Galapagos, AbbVie, Eli Lilly, Pfizer, and Gilead Sciences Inc. MS and AS report no disclosures. Address correspondence to Prof. A. Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, University of California San Diego School of Medicine 9500 Gilman Drive, #0943, La Jolla, CA 92093, USA. Email: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 14, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
Arthur Kavanaugh, Rene R. Westhovens, Kevin L. Winthrop, Susan J. Lee, YingMeei Tan, Di An, Lei Ye, John S. Sundy, Robin Besuyen, Luc Meuleners, Mykola Stanislavchuk, Alberto J. Spindler, Maria Greenwald, Rieke Alten, Mark C. Genovese
The Journal of Rheumatology Feb 2021, jrheum.201183; DOI: 10.3899/jrheum.201183
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
Arthur Kavanaugh, Rene R. Westhovens, Kevin L. Winthrop, Susan J. Lee, YingMeei Tan, Di An, Lei Ye, John S. Sundy, Robin Besuyen, Luc Meuleners, Mykola Stanislavchuk, Alberto J. Spindler, Maria Greenwald, Rieke Alten, Mark C. Genovese
The Journal of Rheumatology Feb 2021, jrheum.201183; DOI: 10.3899/jrheum.201183